Piramal Pharma's US facility inspection concluded with four observations from the FDA. The company expects a voluntary action indicated classification. Piramal Pharma is preparing a response to the regulator. This comes as the company reported a net loss in the September quarter, impacted by its contract development and manufacturing segment. Shares have seen a decline this year.

See Full Page